Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPKIM, Youn H.PRINCE, H. MilesWHITTAKER, SeanHORWITZ, Steven M.DUVIC, MadeleineBECHTER, OliverSANCHES, Jose A.STADLER, RudolfSCARISBRICK, JuliaQUAGLINO, PietroZINZANI, Pier LuigiWOLTER, PascalERADAT, HerbertPINTER-BROWN, Lauren C.ORTIZ-ROMERO, Pablo L.AKILOV, Oleg E.TROTMAN, JudithTAYLOR, KerryWEICHENTHAL, MichaelWALEWSKI, JanFISHER, David C.MCNEELEY, MariseGRU, Alejandro A.WANG, YinghuiPALANCA-WESSELS, Maria CorinnaLISANO, JulieLI, MarthaLIN, Hui-MinLITTLE, MeredithTREPICCHIO, William L.DUMMER, Reinhard2019-04-242019-04-242018BLOOD, v.132, suppl.1, 20180006-4971https://observatorio.fm.usp.br/handle/OPI/31418engrestrictedAccessSuperior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA StudyconferenceObjectCopyright AMER SOC HEMATOLOGY10.1182/blood-2018-99-112847Hematology1528-0020